Sai Parenterals Ltd
- Market cap
- ₹ 2,204 Cr.
- P/E
- 88.9x
- P/B
- 4.52x
- 52-week range
- 400 – 706
- ROE
- 5%
- ROCE
- 5%
- Dividend yield
- 0%
- Debt / equity
- 0.96
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. It is in the business of branded generic formulations and contract development and manufacturing organizational products and services for the domestic and international markets. Its portfolio includes formulation products across various therapeutic areas like cardiovascular, neruopsychiatry, anti-diabetic, respiratory health, antibiotics, vitamins, minerals and supplements analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. In the injectables segment, the Company has capabilities in sterile manufacturing for critical care and antibiotics, which are delivered through dry powder injections, pre-filled syringes, ampules, and vials. It manufactures and sells branded generic formulations to a diverse customer base, including central and state government agencies.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 222 companies →Sai Parenterals Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)88.9 against a typical 32.9: pricier than most peers (1st = cheapest).188th of 220
- Sales growth+103.1% against a typical +17.4% from a year earlier.18th of 199
- Share price, 3 months−9.1% against a typical −1.4%.152nd of 211
- Size₹ 2,204.1 Cr. market value against a typical ₹ 488.8 Cr. (1st = largest).71st of 205
Latest announcements
Exchange filings and their impact on the company.
- Sai to buy majority of Bion Therapeutics with ~Rs 57 cr annualized sales for cash by end-November via subsidiary.
AIAI analysisPositive for shareholdersMedium impact Sai to buy majority of Bion Therapeutics with ~Rs 57 cr annualized sales for cash by end-November via subsidiary.
Sai Parenterals board on 16 Nov 2026 approved signing an agreement through its wholly owned subsidiary SP Analytics to acquire a majority stake in Hyderabad-based Bion Therapeutics India, a branded formulations business. Bion reported turnover of Rs 28.22 cr for H1 to Sep 2026 and total income of Rs 47.29 cr in FY26. The all-cash deal is expected to close by 30 Nov 2026 and will be funded from IPO proceeds earmarked for general corporate purposes plus debt, making Bion a step-down subsidiary.
Why it matters: Majority acquisition of Bion (H1 turnover Rs 28.22 cr, FY25 total income Rs 47.14 cr) adds ~Rs 50-57 cr annualized revenue (~8.5% of TTM Rs 668 cr) and Rs 2-4 cr net profit, funded by IPO GCP proceeds plus new debt, closing by 30 Nov 2026.
For shareholders: Adds ~8% to revenue and diversifies into branded prescription formulations with modest profit accretion offset partly by debt funding.
Estimated effect over the next 12 months
Estimated effect over the next 12 months Metric Now Estimated change Confidence Revenue ₹ 668 Cr. TTM to Sep 2026▲ +7.5% to +8.5% · +₹ 50 Cr. to +₹ 57 Cr. Target H1 turnover Rs 28.22 cr implies ~Rs 56-57 cr annualized; majority/controlling stake implies full consolidation -> ~Rs 50-57 cr in next 12 months vs TTM sales Rs 668 cr65% Operating margin 13% TTM to Sep 2026▲ +0.2 pts to +0.5 pts Branded prescription formulations typically higher margin than Sai TTM OPM 13%; small scale limits blended uplift after integration costs35% Net profit ₹ 25 Cr. TTM to Sep 2026▲ +8% to +16% · +₹ 2 Cr. to +₹ 4 Cr. Rs 57 cr sales at ~8-10% net margin gives Rs 4.5-5.5 cr PAT less interest on debt portion and deal costs -> net +Rs 2-4 cr vs TTM PAT Rs 25 cr45% EPS ₹ 5.64 TTM to Sep 2026▲ +8% to +16% · +₹ 0.45 to +₹ 0.9 Same PAT accretion as net_profit with no new equity (all-cash deal) -> +8-16% on TTM EPS Rs 5.64 = +Rs 0.45-0.9045% Net debt ₹ 374 Cr. Sep 2026 balance sheet borrowings▲ +8% to +16% · +₹ 30 Cr. to +₹ 60 Cr. All-cash price undisclosed, based on independent valuation; assume EV 2-3x sales (~Rs 100-150 cr for 100%); part funded by IPO GCP proceeds, balance by debt -> +Rs 30-60 cr debt vs borrowings Rs 374 cr35% Market cap ₹ 2,204.13 Cr. 2026-11-12▲ +5% to +10% · +₹ 110 Cr. to +₹ 220 Cr. Market typically rewards branded-formulations diversification at 88x PE; ~8% revenue accretion supports 5-10% value uplift if deal completes by 30 Nov 202640% Generated by AI from the original document. It can be wrong or incomplete and is not investment advice. Check the source before acting on it. Estimates are rough projections, not forecasts by Minerva Capital Research Solutions.
Sai Parenterals board on 16 Nov 2026 approved signing an agreement through its wholly owned subsidiary SP Analytics to acquire a majority stake in Hyderabad-based Bion Therapeutics India, a branded formulations business. Bion reported turnover of Rs 28.22 cr for H1 to Sep 2026 and total income of Rs 47.29 cr in FY26. The all-cash deal is expected to close by 30 Nov 2026 and will be funded from IPO proceeds earmarked for general corporate purposes plus debt, making Bion a step-down subsidiary.
- 7 Nov 2026Analysts/Institutional Investor Meet/Con. Call UpdatesHigh impactVery positivePrice +3.6% on 8 NovH1 ahead of Rs 750 cr plan with Q2 margin at 21% and Rs 1506 cr contracted Australia book underpins strong next 12 months as new capacities ramp.
AIAI analysisVery positive for shareholdersHigh impact H1 ahead of Rs 750 cr plan with Q2 margin at 21% and Rs 1506 cr contracted Australia book underpins strong next 12 months as new capacities ramp.
Sai Parenterals reported Q2 FY27 revenue of Rs 196 cr, up 9% sequentially, with gross margin improving to 47.5% and EBITDA margin to 21.1%, taking H1 revenue to Rs 376 cr against a Rs 750 cr full-year target. Management said it will comfortably cross the target and sustain gross margin above 45% and EBITDA above 17%. It also renewed two Australia OTC contracts totalling AUD232m or about Rs 1506 cr, is expanding Unit III capacity by 81% from December 2026, and will commission the Adelaide plant in January 2027 and a new Rs 215 cr injectable facility in July 2027.
Why it matters: Q2 FY27 revenue Rs 196.1 cr up 9% QoQ with gross margin 47.5% and EBITDA margin 21.1% puts H1 at Rs 376 cr toward Rs 750 cr FY27 target, while AUD232m (~Rs 1506 cr) renewals, Unit III +81% to 155m units per month from Dec 2026, and Adelaide commissioning Jan 2027 drive next-12-month growth and margin uplift despite higher depreciation and peak debt.
For shareholders: H1 revenue and 17.6% EBITDA margin already ahead of full-year guides with large multi-year contracts and 81% capacity expansion ramping in next 12 months.
Estimated effect over the next 12 months
Estimated effect over the next 12 months Metric Now Estimated change Confidence Revenue ₹ 381 Cr. FY26▲ +118% to +136% · +₹ 450 Cr. to +₹ 520 Cr. H1 FY27 Rs 376 cr is ~50% of Rs 750 cr FY27 target, mgmt says comfortably crossing; H2 FY27 ~380-400 cr plus H1 FY28 ramp from Unit III and Adelaide support -> ~830-900 cr next 12m vs FY26 Rs 381 cr75% Operating margin 10% FY26▲ +7 pts to +8.5 pts H1 FY27 EBITDA margin 17.6% with Q2 at 21.1% vs Q1 13.7% on gross margin 47.5% from inventory FIFO and ERP controls; mgmt guides gross >45% and EBITDA >17% and Adelaide in-housing to lift manufacturing margin70% Net profit ₹ 14 Cr. FY26▲ +250% to +328% · +₹ 35 Cr. to +₹ 46 Cr. H1 FY27 PAT Rs 18.4 cr already above FY26 Rs 14 cr despite depreciation Rs 33.2 cr; H2 seasonally stronger plus Unit III Q4 ramp, partly offset by high depreciation Rs 25 cr per quarter and interest ~Rs 9 cr per quarter -> next 12m PAT ~50-60 cr65% EPS ₹ 3.23 FY26▲ +201% to +263% · +₹ 6.5 to +₹ 8.5 H1 FY27 EPS Q1 1.79 + Q2 2.38 = 4.17 already above FY26 3.23; next 12m PAT ~50-60 cr on expanded post-IPO share base implies EPS ~10-1260% Net debt ₹ 528.14 Cr. LFY as of 2026-11-05▲ +7.5% to +17% · +₹ 40 Cr. to +₹ 90 Cr. Total borrowings Rs 357 cr Sep 2026 vs ~Rs 320 cr Mar 2026 with cash Rs 129 cr; FY26 peak debt year, Saicriti Rs 215 cr project debt at subsidiary to be drawn plus Adelaide balance AUD7m, partly offset by operating cash60% Order book — No baseline disclosed in company context▲ +₹ 1,506 Cr. Renewed Australia OTC contracts AUD232m ~Rs 1506 cr (EBOS AUD202m for 7.5 years + Wesfarmers AUD30m ~Rs 204 cr for 3 years) with expanded portfolio and 451 TGA dossiers; underpins multi-year contracted revenue85% Working capital 208 days FY26 Cash Conversion Cycle▼ −33.6% to −19.2% · −70 to −40 Adelaide to cut inventory from 9-10 months to 5-6 months (~120 days saving) on ~70% Australia export share plus Q2 export receivables bunching in last 1-1.5 months to normalise in Q3-Q4; domestic 120-150 days targeted below 120 days60% Capex ₹ 646 Cr. Sep 2026 (Fixed Assets Rs 377 cr + CWIP Rs 269 cr)▲ +27.8% to +34% · +₹ 180 Cr. to +₹ 220 Cr. Spent ~Rs 70 cr in H1 FY27 on Adelaide and Unit III; balance Adelaide AUD7m of AUD53m plus Saicriti Rs 215 cr injectable facility to July 2027 and Unit III commissioning Dec 202675% Net worth ₹ 496 Cr. Sep 2026 (Equity Rs 312 cr + Reserves Rs 184 cr)▲ +8.1% to +11.1% · +₹ 40 Cr. to +₹ 55 Cr. No dividend; retained PAT ~Rs 50-60 cr next 12m adds to net worth; IPO proceeds already capitalised and 60% stakes in Saicriti and Sai Prathyak completed70% Generated by AI from the original document. It can be wrong or incomplete and is not investment advice. Check the source before acting on it. Estimates are rough projections, not forecasts by Minerva Capital Research Solutions.
Sai Parenterals reported Q2 FY27 revenue of Rs 196 cr, up 9% sequentially, with gross margin improving to 47.5% and EBITDA margin to 21.1%, taking H1 revenue to Rs 376 cr against a Rs 750 cr full-year target. Management said it will comfortably cross the target and sustain gross margin above 45% and EBITDA above 17%. It also renewed two Australia OTC contracts totalling AUD232m or about Rs 1506 cr, is expanding Unit III capacity by 81% from December 2026, and will commission the Adelaide plant in January 2027 and a new Rs 215 cr injectable facility in July 2027.
- H1 revenue and profit already beat FY26 full year, pointing to ~2x sales and earnings run-rate.
AIAI analysisVery positive for shareholdersHigh impact H1 revenue and profit already beat FY26 full year, pointing to ~2x sales and earnings run-rate.
Sai Parenterals reported Q2 FY27 consolidated revenue of Rs 194 crore versus Rs 53.5 crore a year ago and PAT of Rs 10.5 crore versus Rs 6.35 crore, taking H1 revenue to Rs 373.6 crore and PAT to Rs 18.4 crore, already above FY26 full-year profit. Operating cash flow was sharply negative at minus Rs 205 crore in H1 as receivables surged and cash fell to Rs 129 crore, while CWIP stood at Rs 269 crore. The board also completed the 60% acquisition of Saicriti Pharma making it a subsidiary and approved buying the balance 25% of SP Analytics for Rs 25,000 to make it wholly owned.
Why it matters: H1 FY27 consolidated revenue Rs 373.6 cr is ~98% of FY26 full-year Rs 381 cr and H1 PAT Rs 18.4 cr exceeds FY26 PAT Rs 14.3 cr, with completion of 60% Saicriti Pharma acquisition and move to 100% of SP Analytics, indicating a high-scale earnings step-change.
For shareholders: Revenue run-rate doubling and H1 profit exceeding prior full year dominates near-term cash-flow and debt strain.
Estimated effect over the next 12 months
Estimated effect over the next 12 months Metric Now Estimated change Confidence Revenue ₹ 3,809.98 Cr. FY ended Mar 2026▲ +92% to +110% · +₹ 3,500 Cr. to +₹ 4,200 Cr. H1 FY27 revenue Rs 3735.9 mn is ~98% of FY26 revenue Rs 3810 mn; Q2 Rs 1940.2 mn vs Rs 535.3 mn YoY; annualising H1 run-rate implies ~Rs 7470 mn in next 12 months -> +~96% on FY26 baseline75% Operating margin 10% FY ended Mar 2026▲ +6 pts to +8 pts H1 FY27 EBITDA ~Rs 638 mn (PBT 196.79 + finance 183.42 + depreciation 332 - other income 74.6) on Rs 3735.9 mn = ~17.1% vs FY26 ~9.3%; assume 16-18% sustains -> +6-8pp on 10% FY26 OPM65% Net profit ₹ 142.59 Cr. FY ended Mar 2026▲ +147% to +182% · +₹ 210 Cr. to +₹ 260 Cr. H1 PAT Rs 184.33 mn already exceeds FY26 PAT Rs 142.59 mn; Q2 Rs 105.1 mn vs Rs 63.5 mn YoY +65%; annualised H1 ~Rs 369 mn -> +~159% on FY26 baseline70% EPS ₹ 3.23 FY ended Mar 2026▲ +139% to +180% · +₹ 4.5 to +₹ 5.8 H1 basic EPS Rs 4.17 already exceeds FY26 Rs 3.23; annualising H1 implies ~Rs 8.3 vs 3.23 baseline -> +~157%; range for share-count changes after listing65% Working capital −161 days FY ended Mar 2026▲ +200 to +260 H1 trade receivables +Rs 734.9 mn to Rs 2545.3 mn, inventories +Rs 74.9 mn, operating cash flow -Rs 2054.6 mn; cycle moving from -161 days to positive -> +200-260 days tied up55% Capex ₹ 576 Cr. Mar 2026▲ +26% to +43% · +₹ 150 Cr. to +₹ 250 Cr. PPE+CWIP rose ~Rs 780 mn in H1 to Rs 3518.5 mn with CWIP Rs 2692.7 mn; ongoing project spend implies +Rs 150-250 cr in next 12 months -> +26-43% on Rs 576 cr (364+212) baseline60% Net debt ₹ 528.14 Cr. FY26▲ +28.4% to +47.3% · +₹ 150 Cr. to +₹ 250 Cr. H1 cash fell Rs 2876 mn to Rs 1293.3 mn on negative operating cash flow and Rs 698 mn investing outflow while total borrowings ~Rs 3566 mn; continued capex and working capital funding to lift net debt55% Generated by AI from the original document. It can be wrong or incomplete and is not investment advice. Check the source before acting on it. Estimates are rough projections, not forecasts by Minerva Capital Research Solutions.
Sai Parenterals reported Q2 FY27 consolidated revenue of Rs 194 crore versus Rs 53.5 crore a year ago and PAT of Rs 10.5 crore versus Rs 6.35 crore, taking H1 revenue to Rs 373.6 crore and PAT to Rs 18.4 crore, already above FY26 full-year profit. Operating cash flow was sharply negative at minus Rs 205 crore in H1 as receivables surged and cash fell to Rs 129 crore, while CWIP stood at Rs 269 crore. The board also completed the 60% acquisition of Saicriti Pharma making it a subsidiary and approved buying the balance 25% of SP Analytics for Rs 25,000 to make it wholly owned.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB- by Acuite- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| Acuite | ACUITE BBB- | Stable | 19 Nov 2026 |
| Rating | Details | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 Nov 2026 | ▲ Upgrade | ACUITE BBB- | Medium | Acuite | ₹ 9 Cr. | |||||||||||||||||||||||||||||||||||||||||
Rating details
Acuite upgraded Sai Parenterals to BBB-/A3 on strong export and CDMO growth post-IPO, with stable outlook. Acuite upgraded Sai Parenterals' Rs 9 crore bank facilities to BBB- (stable) for long term and A3 for short term, up from B- and A4, after the company resumed cooperation. The agency cited sharp growth to Rs 382 crore revenue in FY26 and Rs 374 crore in H1FY27 on export and CDMO traction plus the Noumed acquisition in Australia-New Zealand, healthy net worth after the April 2026 IPO, and adequate liquidity with large cash balances. It flagged intensive working capital, moderated margins, elevated debt from expansion and acquisitions, and project execution and regulatory risks. Why it matters: Upgrade from B-/A4 to BBB-/A3 on Rs 9 cr facilities reflects exit from non-cooperation, FY26 revenue Rs 382.19 cr vs Rs 163.11 cr on Noumed acquisition and CDMO growth, H1FY27 Rs 373.59 cr at 17.07% EBITDA, net worth Rs 322.59 cr post April-26 IPO, Rs 571 cr capex plan and Rs 80-110 cr expected accruals vs Rs 15-22 cr repayments, tempered by 779-day GCA, 1.45x gearing and execution/regulatory risks. For shareholders: Multi-notch upgrade validates scale-up, IPO-strengthened net worth and adequate liquidity despite intensive working capital and high debt. Estimated effect over the next 12 months
Generated by AI from the original document. It can be wrong or incomplete and is not investment advice. Check the source before acting on it. Estimates are rough projections, not forecasts by Minerva Capital Research Solutions. | ||||||||||||||||||||||||||||||||||||||||||||||
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 1 Nov 2026 | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 30 Sep 2026 | General | — |
| 11 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 23 May 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 20 Apr 2026 | Other business matters | To consider other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2025 | Sep 2026 |
|---|---|---|---|---|---|---|
| Sales | 33 | 96 | 198 | 179 | 54 | 195 |
| Expenses | 29 | 100 | 172 | 155 | 42 | 155 |
| Operating Profit | 5 | −4 | 26 | 24 | 11 | 40 |
| OPM % | 14% | −3.7% | 13% | 13% | 21% | 21% |
| Other Income | 1 | 3 | 3 | 4 | 1 | 4 |
| Interest | 2 | 5 | 8 | 9 | 2 | 9 |
| Depreciation | 1 | 6 | 8 | 8 | 1 | 25 |
| Profit before tax | 2 | −12 | 12 | 10 | 9 | 10 |
| Tax % | 30% | −43% | −6% | 19% | 31% | −6% |
| Net Profit | 1 | −7 | 13 | 8 | 6 | 11 |
| EPS in Rs | 0.52 | −1.8 | 2.98 | 1.79 | 1.72 | 2.38 |
| YoY Sales growth | — | — | — | 435 | — | 264 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 58%
- TTM
- 134%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 48%
- TTM
- −1%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 9%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Sai Parenterals Ltd | ₹ 494.00 | ₹ 2,204 Cr. | 88.9x | 4.5x | 5% | — |
| Sun Pharmaceutical Industries | ₹ 1,880.00 | ₹ 4,51,064 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 11,442.00 | ₹ 3,03,749 Cr. | 73x | 11.4x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,662.15 | ₹ 1,77,327 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,391.80 | ₹ 1,12,438 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,189.90 | ₹ 1,18,693 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Anil Kumar Karusala
- Executive Chairman, Managing Director
- D.B.Venkoji Prakash
- Chief Executive Officer
- Anil Kumar
- Chief Financial Officer
- Shivali Aggarwal
- Company Secretary, Compliance Officer
- Vijitha Gorrepati
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.